AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is ...

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study ...

Patients with COPD are at increased risk for infections, making avoidance and effective treatments key in management.

Thirteen years after his passing, Sir David Jack still looms as an innovative force in healthcare. Wednesday, when the FDA approved Verona Pharma’s Ohtuvayre (ensifentrine) to treat chronic ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD ...

Many people with COPD can control their symptoms by using inhaled medicines each day. But inhaled medicines may not offer enough relief for people who also have high levels of a type of white blood ...

Background Balloon pulmonary angioplasty (BPA) improves haemodynamics in patients with inoperable chronic thromboembolic ...

Among adults with undiagnosed respiratory symptoms, those with undiagnosed COPD and asthma vs. preserved ratio impaired or ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca has launched a Phase II clinical study titled ‘A Phase II, ...